1. Scrip
  2. >>New Products

10 Drug Launch Flops Of The Decade

 
• By Jessica Merrill

The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.

Emoji face that is a little bit sad, with a slight frown and neutral eyes on yellow background
Not every launch is a commercial success • Source: Shutterstock

What does it take for a drug to make Scrip's list of 10 of the worst launches of the decade? It means that a drug that was launched between 2010 and 2019 became a commercial dud – at least initially, in the first two years on the market. Maybe the drug failed to live up to expectations because the drug's maker was unprepared for the launch, the drug's safety and efficacy profile were out of balance, or the pricing and reimbursement strategy for that matter. But generally, the warning signs were in place and the drug maker simply failed to heed them early enough.

Dendreon Corp.'s hyped prostate cancer immunotherapy Provenge (sipuleucel-T) broke the cancer drug price ceiling when it launched in 2012 at an annual price of $93,000 – and then it crashed back to earth

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.